Tamarixetin Attenuated the Virulence of Staphylococcus aureus by Directly Targeting Caseinolytic Protease P

Area of Science:

• Microbiology
• Biochemistry
• Pharmacology

Background:

• Staphylococcus aureus infections, particularly drug-resistant strains, pose a significant global health threat.
• Antivirulence therapies targeting essential pathogenicity factors are a focus for combating S. aureus.
• Caseinolytic protease P (ClpP) is a crucial hydrolase for S. aureus virulence.

Purpose of the Study:

• To investigate tamarixetin as a potential inhibitor of S. aureus ClpP.
• To evaluate the antivirulence effects of tamarixetin against S. aureus.
• To assess the therapeutic potential of tamarixetin in vivo.

Main Methods:

• Screening of flavonoid compounds for ClpP inhibition.
• Biochemical assays to determine IC50 and dissociation constant (KD) of tamarixetin.
• Gene transcription and protein expression analysis.
• In vitro hemolytic activity assays.
• In vivo mouse model of S. aureus pneumonia.
• Combination therapy assessment with cefotaxime.

Main Results:

• Tamarixetin inhibited ClpP activity (IC50 = 49.73 μM) without affecting bacterial growth or causing cytotoxicity.
• Tamarixetin suppressed virulence gene transcription (hla, agr, RNAIII, pvl, PSM-α, spa) and protein expression (Hla, PVL).
• Tamarixetin inhibited S. aureus hemolytic activity, increased urease expression, and demonstrated binding affinity to ClpP (KD = 2.52 × 10^-6 M).
• In vivo studies showed tamarixetin improved survival in a mouse pneumonia model and reduced bacterial load.
• Tamarixetin enhanced the efficacy of cefotaxime in combination therapy.

Conclusions:

• Tamarixetin is a potent ClpP inhibitor with significant antivirulence properties against S. aureus.
• Tamarixetin demonstrates therapeutic potential for treating S. aureus infections, including drug-resistant strains.
• Tamarixetin represents a promising candidate for developing novel antivirulence therapies.